Valeritas Holdings Inc. (fka VLRXQ)

[Sumfest]

Valeritas Announces V-Go® is Preferred on Humana Part D Formularies

BRIDGEWATER, N.J., Jan. 03, 2019 (GLOBE NEWSWIRE) -- Valeritas Holdings, Inc. (VLRX), a medical technology company and maker of V-Go® Wearable Insulin Delivery device, a simple, affordable, all-in-one insulin delivery option that is worn like a patch for patients with diabetes, today announced that Humana, one of the nation’s leading health and well-being companies in the United States, has given V-Go Preferred status on Humana’s Part D formularies.

“We are very excited that V-Go is now Preferred on Humana’s Medicare formularies, which will improve patient access to V-Go at an affordable monthly copay for its members with type 2 diabetes,” said Valeritas CEO, John Timberlake.

V-Go is available as Preferred on Humana’s Part D formularies, which include their MAPD and Enhanced PDP formularies.